Healthcare science conference
-
Upload
scott-elliott -
Category
Documents
-
view
15 -
download
1
Transcript of Healthcare science conference
Research Laboratory
The Laboratory Research Team:Specialist Biomedical Scientist Scott ElliottPost-doctoral Research Scientist Dr Sharon GlaysherResearch Associate Practitioner Lis Connell
Ian Gedge
Our Backgrounds
Translational Oncology Research LaboratoryTORC
Respiratory Trials – Scott Elliott
Translational Research Laboratory
Pathology
Clinical Pathology
• Blood Sciences• Cellular Pathology
(including Cancer Laboratory)
• Microbiology
F-Level Research lab
• Service Development and Translation
• Respiratory research service• Clinical trial service support• PHT Hosted/Led Laboratory
Research• Innovation
Research Lab Resources/capabilityProcessing- Centrifuges – blood spinning etc- General laboratory equipment- Liquid N2 (for “snap-freezing”)- Dry ice (frozen shipment)Storage- -80C and -20C freezer - Fridges- Long and short termScientific Capability- Cell Culture- Molecular Biology (PCR)- Protein assays/ ELISA’s- Microscopy- Mutation Analysis- Cytological analysis – e.g. phenotyping patients with inflammatory airways
diseasesGeneral- Postgraduate student project support and supervision- Collaborations and Grant writing - Support for PHT initiated laboratory studies
• Stratified Medicine• Biomarkers• Cancer• Long-term respiratory conditions• Innovation• Translation
Our Scientific Areas of interest
PHT Based Laboratory Studies- Past / Present and Future
Breast Sentinel Lymph Node Assay
(First trust to translate into clinical practice)
Thyroid Cancer- BRAF on FNA samples
(First trust to translate into prospective use)
Mesothelioma Biomarker Discovery
(Novel multi biomarker approach in progress)
Cardiology Biomarkers
(MD studies Ongoing)
Asthma Differential
Counts(Now used clinically)
Stratified Cancer Therapies
(Nurse Led PhD Programme, Future work)
Transcription Factors (BBSRC Grant)
SENSOR (e-Health)
Prostate Biomarkers(Br J Cancer. 2012)
Asthma Urine Dipstick Test
(Patent Pending)
Efficacy of Anti-Cancer Drugs
(>40 publications over 10 years)
Dendritic Cell Immunology
(European funding)
Ovarian Biomarker Discovery
(MTOC Study in progress)
Asthma Deaths
(PhD Research)
Flow Cytometry and SELDI-TOF(Ongoing Respiratory Studies)
HER2 Testing in Breast Cancer
(now used Clinically)
Predictive peptide“Typical” pattern
Cancer Biomarkers – What’s so special?
PICK ME, PICK ME !
Molecular Targeted Therapies in Ovarian Cancer;
identifying potential biomarkers and overcoming mechanisms of resistance
Assess Tumour Cell Drug Sensitivity
Biomarkers- Search for drug sensitivity prediction
Cell Based Assays
Gene Expression Mutations
Assess Tumour Cell Drug Sensitivity
bevacizamab Dasatinib
Gefitinib ZSTK474
Lapatinib ZSTK474
crizotinib Dasatinib
Gefitinib Linsitinib
Lapatinib Linsitinib
ZSTK474 Linsitinib
olaparib Gefitinib
olaparib Lapatinib
cabozantinib ZSTK474
cabozantinib Trametinib
ruxolitinib everolimus
dabrafenib trametinib
ruxolitinib Trametinib
Dovitinib Trametinib
MK-1775 olaparib
VEGF A BCR-ABL/SRC
EGFR PI3K
EGFR, HER2 PI3K
MET, ROS1 BCR-ABL/SRC
EGFR IGF1R/IR
EGFR, HER2 IGF1R/IR
PI3K IGF1R/IR
PARP EGFR
PARP EGFR, HER2
FLT3, MET, VEGFR PI3K
FLT3, MET, VEGFR MEK/MAPK/ERK
JAK1/2 mTOR
RAF MEK/MAPK/ERK
JAK1/2 MEK/MAPK/ERK
FGFR1/2/3 MEK/MAPK/ERK
WEE-1 PARP
Drug Combinations Target Combinations
Multiple Targets Better Results
EGFR inhibitors – Gefitinib & Erlotinib PI3K inhibitor – ZSTK474
Sensitive
Resistant
WALK TO VICTORY
Research maybe hard work, demand long hours and lots of repetition
But with the incredible extended collaborative team we have here at Portsmouth, there is always fun to be had